Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to 325.44%.

  • Editas Medicine's EBITDA Margin rose 1073237400.0% to 325.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 428.71%, marking a year-over-year decrease of 586800.0%. This contributed to the annual value of 777.22% for FY2024, which is 5606700.0% down from last year.
  • Latest data reveals that Editas Medicine reported EBITDA Margin of 325.44% as of Q3 2025, which was up 1073237400.0% from 1440.58% recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's EBITDA Margin registered a high of 39.9% during Q4 2023, and its lowest value of 136952.38% during Q3 2022.
  • Over the past 5 years, Editas Medicine's median EBITDA Margin value was 940.09% (recorded in 2023), while the average stood at 15270.04%.
  • As far as peak fluctuations go, Editas Medicine's EBITDA Margin crashed by -1363189600bps in 2022, and later soared by 1360122900bps in 2023.
  • Over the past 5 years, Editas Medicine's EBITDA Margin (Quarter) stood at 333.71% in 2021, then plummeted by -191bps to 970.72% in 2022, then surged by 96bps to 39.9% in 2023, then plummeted by -282bps to 152.24% in 2024, then crashed by -114bps to 325.44% in 2025.
  • Its EBITDA Margin was 325.44% in Q3 2025, compared to 1440.58% in Q2 2025 and 1635.1% in Q1 2025.